The Department of Health and Social Care (DHSC) has added further 28 new products to the list of ‘Drugs for which Discount is Not Deducted’ (DND) in Part II of the Drug Tariff from 1 August 2022.
PSNC said, “It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, accordingly.”
The 28 products added to DND list on 1 August 2022:
- Adrenaline (base) 500micrograms/0.5ml (1 in 1,000) solution for injection ampoules
- Amantadine 50mg/5ml oral solution sugar free
- Amiloride 5mg / Bumetanide 1mg tablets
- Cabergoline 1mg tablets
- Cabergoline 2mg tablets
- Chloral hydrate 500mg/5ml oral solution
- Doxepin 10mg capsules
- Efmody 10mg modified-release capsules
- Efmody 5mg modified-release capsules
- Ephedrine hydrochloride 15mg tablets
- Ephedrine hydrochloride 30mg tablets
- Hydrocortisone 0.5% ointment
- Liothyronine 10microgram capsules
- Liothyronine 20microgram capsules
- Liothyronine 5microgram capsules
- Naproxen 125mg/5ml oral suspension sugar free
- Ontozry 100mg tablets
- Ontozry 12.5mg/25mg tablets treatment initiation pack
- Ontozry 150mg tablets
- Ontozry 200mg tablets
- Ontozry 50mg tablets
- Potassium dihydrogen phosphate 13.6% (potassium 10mmol/10ml) solution for infusion 10ml ampoules
- Prednsiolone sodium phosphate 5mg suppositories
- Procyclidine 10mg/2ml solution for injection ampoules
- Rupatadine 10mg tablets
- Tamoxifen 40mg tablets
- Vazkepa 998mg capsules
A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.
Helen Morgan MP highlighted that alarming rate of pharmacy closures
